Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rat, Human, Mouse, Bovine, Dog, Chicken, Xenopus (tested or 100% immunogen sequence identity)
Western blot (1:1000)
Specificity and Use
GAP43 antibody was raised against phosphopeptide corresponding to amino acid residues surrounding the phosphoSer4 of Gap-43.
Specific for the ~50k Gap-43 protein phosphorylated at Ser41. In some tissues the antibody also recognizes a higher molecular weight protein that is also recognized by the pan Gap-43 antibody, that may be a Gap-43 aggregate or oligomer. Immunolabeling is blocked by the phosphopeptide used as antigen but not by the corresponding
50 uL of 10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1 mg/mL BSA, 50% glycerol.
Western blot of rat cortex lysate showing specific immunolabeling of the ~50k Gap-43 protein phosphorylated at Ser41 (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: lambda phosphatase).
Western blot of rat cortex lysate showing specific immunolabeling of the ~50k Gap-43 protein phosphorylated at Ser41 (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: l-Ptase). The blot is identical to the control except that it was incubated in l-Ptase (1200 units for 30 min) before being exposed to the Anti-Ser41 GAP-43. The immunolabeling is completely eliminated by treatment with l-Ptase.
Requested From: United States
Date Requested: 9/27/2016